Bain Capital Life Sciences Investors
Latest statistics and disclosures from Bain Capital Life Sciences Investors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SWTX, Atea Pharmaceuticals, ARQT, MRSN, ANNX, and represent 65.76% of Bain Capital Life Sciences Investors's stock portfolio.
- Added to shares of these 10 stocks: Atea Pharmaceuticals (+$235M), SYRS (+$63M), C4 Therapeutics (+$54M), Dynavax Technologies Corp option (+$49M), SLDB (+$24M), APTX (+$12M), Bcls Acquisition Corp (+$5.4M), Frazier Lifesciences Acquis, Jiya Acquisition Corp, Helix Acquisition Corp.
- Started 8 new stock positions in SYRS, Bcls Acquisition Corp, C4 Therapeutics, Atea Pharmaceuticals, Helix Acquisition Corp, Dynavax Technologies Corp option, Frazier Lifesciences Acquis, Jiya Acquisition Corp.
- Reduced shares in these 7 stocks: REPL (-$49M), DVAX (-$47M), SAGE (-$31M), DRNA (-$22M), KYMR (-$16M), PANA.U, Marinus Pharmaceuticals.
- Sold out of its positions in DVAX, PANA.U, REPL, SAGE.
- Bain Capital Life Sciences Investors was a net buyer of stock by $282M.
- Bain Capital Life Sciences Investors has $1.6B in assets under management (AUM), dropping by 48.45%.
Tip: Access up to 7 years of quarterly data
Positions held by Bain Capital Life Sciences Investors, LLC consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Bain Capital Life Sciences Investors
Companies in the Bain Capital Life Sciences Investors portfolio as of the December 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Springworks Therapeutics (SWTX) | 33.2 | $528M | 7.3M | 72.52 | ||
| Atea Pharmaceuticals | 14.7 | $235M | NEW | 5.6M | 41.78 | |
| Arcutis Biotherapeutics (ARQT) | 7.0 | $112M | 4.0M | 28.13 | ||
| Mersana Therapeutics (MRSN) | 5.8 | $92M | 3.4M | 26.61 | ||
| Annexon (ANNX) | 5.1 | $81M | 3.2M | 25.03 | ||
| Dicerna Pharmaceuticals (DRNA) | 4.3 | $68M | -24% | 3.1M | 22.03 | |
| Syros Pharmaceuticals (SYRS) | 3.9 | $63M | NEW | 5.8M | 10.85 | |
| C4 Therapeutics Com Stk | 3.4 | $54M | NEW | 1.6M | 33.13 | |
| Solid Biosciences (SLDB) | 3.4 | $54M | +82% | 7.1M | 7.58 | |
| Dynavax Technologies Corp option | 3.0 | $49M | NEW | 11M | 4.45 | |
| Nurix Therapeutics (NRIX) | 2.7 | $42M | 1.3M | 32.88 | ||
| Constellation Pharmceticls I (CNST) | 2.5 | $40M | 1.4M | 28.80 | ||
| Aptinyx (APTX) | 1.9 | $31M | +59% | 8.9M | 3.46 | |
| Kymera Therapeutics (KYMR) | 1.9 | $30M | -34% | 480k | 62.00 | |
Setup an alertBain Capital Life Sciences Investors will file the next quarterly 13-HR in about 3 months. Would you like to be notified? |
||||||
| Aeglea Biotherapeutics (AGLE) | 1.3 | $21M | 2.7M | 7.87 | ||
| Marinus Pharmaceuticals | 1.1 | $18M | 1.4M | 12.20 | ||
| Crinetics Pharmaceuticals In (CRNX) | 0.9 | $15M | 1.1M | 14.11 | ||
| Therapeutics Acquisition Cor Com Cl A (RACA) | 0.9 | $14M | 1.0M | 13.92 | ||
| Arya Sciences Acquisition Corp Iii Com Cl A (ARYA) | 0.7 | $11M | 1.0M | 10.85 | ||
| X4 Pharmaceuticals (XFOR) | 0.7 | $11M | 1.6M | 6.43 | ||
| Savara (SVRA) | 0.4 | $5.9M | 5.1M | 1.15 | ||
| Bctg Acquisition Corp (BCTG) | 0.4 | $5.7M | 500k | 11.44 | ||
| Bcls Acquisition Corp Com Cl A | 0.3 | $5.4M | NEW | 488k | 11.14 | |
| Frazier Lifesciences Acquisition Corp Unit 12/09/2025 | 0.2 | $3.1M | NEW | 300k | 10.38 | |
| Jiya Acquisition Corp Com Cl A | 0.2 | $3.1M | NEW | 300k | 10.30 | |
| Helix Acquisition Corp Com Cl A | 0.2 | $2.8M | NEW | 250k | 11.37 | |
Past Filings by Bain Capital Life Sciences Investors
SEC 13F filings are viewable for Bain Capital Life Sciences Investors going back to 2017
- Bain Capital Life Sciences Investors 2020 Q4 filed Feb. 16, 2021
- Bain Capital Life Sciences Investors 2020 Q3 filed Nov. 16, 2020
- Bain Capital Life Sciences Investors 2020 Q2 filed Aug. 14, 2020
- Bain Capital Life Sciences Investors 2020 Q1 filed May 15, 2020
- Bain Capital Life Sciences Investors 2019 Q4 filed Feb. 14, 2020
- Bain Capital Life Sciences Investors 2019 Q3 filed Nov. 14, 2019
- Bain Capital Life Sciences Investors 2019 Q2 filed Aug. 14, 2019
- Bain Capital Life Sciences Investors 2019 Q1 filed May 15, 2019
- Bain Capital Life Sciences Investors 2018 Q4 filed Feb. 14, 2019
- Bain Capital Life Sciences Investors 2018 Q3 filed Nov. 14, 2018
- Bain Capital Life Sciences Investors 2018 Q2 filed Aug. 14, 2018
- Bain Capital Life Sciences Investors 2018 Q1 filed May 15, 2018
- Bain Capital Life Sciences Investors 2017 Q4 filed Feb. 14, 2018